| LP262847-9 | Guidance for thoracentesis+insertion of tube | COMPONENT | 1 |
| LP262848-7 | Guidance for thoracentesis | COMPONENT | 1 |
| LP262854-5 | Nerve | SYSTEM | 1 |
| LP263143-2 | 3,4,5-trimethylphenyl methylcarbamate | COMPONENT | 1 |
| LP263144-0 | Beta-N-acetylhexosaminidase.A and beta-N-acetylhexosaminidase panel | COMPONENT | 2 |
| LP263145-7 | 2,3,5-trimethylphenyl methylcarbamate | COMPONENT | 1 |
| LP263146-5 | Alpha benzene hexachloride | COMPONENT | 1 |
| LP263147-3 | Borrelia burgdorferi Ab and Anaplasma phagocytophilum, Babesia microti and Ehrlichia chaffeensis IgG panel | COMPONENT | 1 |
| LP263148-1 | Babesia microti and B. divergens+MO-1 and B. duncani 18S rRNA gene panel | COMPONENT | 1 |
| LP263149-9 | Anaplasma phagocytophilum and Ehrlichia sp DNA panel | COMPONENT | 1 |
| LP263150-7 | Haloperidol and reduced haloperidol panel | COMPONENT | 1 |
| LP263151-5 | HYDROcodone and metabolites panel | COMPONENT | 1 |
| LP263152-3 | Guidance for retrieval of foreign body | COMPONENT | 1 |
| LP263154-9 | Famphur | COMPONENT | 1 |
| LP263156-4 | Neutrophil cytoplasmic Ab.IgG and Saccharomyces cerevisiae IgA and IgG | COMPONENT | 1 |
| LP263157-2 | IgA, IgA1 and IgA2 panel | COMPONENT | 1 |
| LP263165-5 | Pregabalin/Creatinine | COMPONENT | 2 |
| LP263196-0 | Oxaprozin | COMPONENT | |
| LP263197-8 | Aspergillus fumigatus and Saccharopolyspora rectivirgula and Thermoactinomyces vulgaris IgG panel | COMPONENT | 1 |
| LP263199-4 | REMS administrative information | COMPONENT | 1 |
| LP263200-0 | REMS requirements | COMPONENT | 1 |
| LP263201-8 | REMS participant requirements | COMPONENT | 1 |
| LP263202-6 | 1,25-Dihydroxyvitamin D and 1,25-Dihydroxyvitamin D2 and 1,25-Dihydroxyvitamin D3 panel | COMPONENT | 1 |
| LP263203-4 | REMS applicant requirements | COMPONENT | 1 |
| LP263204-2 | Sjogrens syndrome-A and B extractable nuclear IgG panel | COMPONENT | 1 |
| LP263205-9 | Thyroglobulin and thyroperoxidase Ab panel | COMPONENT | 1 |
| LP263206-7 | Protein S Ag and protein S Ag.free panel | COMPONENT | 1 |
| LP263207-5 | Epstein Barr virus Ab panel | COMPONENT | 2 |
| LP263208-3 | Triggered care area included in care plan | COMPONENT | 1 |
| LP263209-1 | Items from the most recent prior OBRA or scheduled PPS Assessment | COMPONENT | 1 |
| LP263210-9 | Care area triggered | COMPONENT | 1 |
| LP263214-1 | Date on existing record to be modified or inactivated | COMPONENT | 1 |
| LP263215-8 | RN asessment coordinator attestation of completion | COMPONENT | 1 |
| LP263216-6 | Attesting individual first name | COMPONENT | 1 |
| LP263217-4 | Attesting individual last name | COMPONENT | 1 |
| LP263218-2 | Attesting individual title | COMPONENT | 1 |
| LP263219-0 | Attestation date | COMPONENT | 1 |
| LP263220-8 | Endosulfan II | COMPONENT | 1 |
| LP263221-6 | Endosulfan I | COMPONENT | 1 |
| LP263227-3 | Legal name of patient - first and last | COMPONENT | 1 |
| LP263228-1 | Correction attestation section | COMPONENT | 1 |
| LP263229-9 | Disulfoton | COMPONENT | 1 |
| LP263230-7 | Type of assessment on existing record to be modified or inactivated | COMPONENT | 1 |
| LP263231-5 | Narasin | COMPONENT | 1 |
| LP263232-3 | Zearalenone | COMPONENT | 1 |
| LP263233-1 | Zearalenol | COMPONENT | 1 |
| LP263234-9 | Deoxynivalenol | COMPONENT | 1 |
| LP263235-6 | T-2 toxin | COMPONENT | 1 |
| LP263236-4 | Ochratoxin A | COMPONENT | 1 |
| LP263237-2 | Nivalenol | COMPONENT | 1 |